US macro
Take
Saturday, August 22, 2026
Moderna is a $56B oncology option with a $145M vaccine P&L. Aug 19 P3 melanoma hit; Aug 5 flu approval; Q2 −$782M. Spot $145 is −18% from $177, +550% from $22, and $27 above a $118 mean that has not fully marked the P3. Trade defined. 96% IV does not forgive ATM.
Last cash session Friday Aug 21 · close $145.13 · +$11.81 · 87M shares
Price
MRNA
6M +230.37%
Snapshot
P3 week, stale street mean
Market cap
$56.0B
vs 52-week
-17.85%
Q2 revenue
$145M
+2%
Q2 net loss
$782M
Cash 6/30
$6.9B
YE cash
$4.7–5.2B
P3 melanoma
Hit
Aug 19
Flu FDA
Aug 5
Street
22 analysts
$118
Mean target · -18.69% vs spot
High $210 · Low $42 · Median $105
8
Buy
10
Hold
4
Sell
Hold
tilt
Next
Aug 28 expiry
2026-08-28
150C / 90–110P. First pin after the gap. IV 96 will crush if nothing hits.
News
MRNA headlines
No headlines cleared the filter.
Street
Analyst actions
| Date | Firm | Action | Target |
|---|---|---|---|
| 08-20 | Jefferies | Buy, PT raised | $190from 110 |
| 08-20 | Leerink | Outperform | $175 |
| 08-19 | Morgan Stanley | Equal-weight, PT raised | $140from 85 |
| 08-06 | Bank of America | Neutral | $95 |
| 07-31 | JPMorgan | Neutral | $90 |
| 07-31 | Goldman | Sell | $55 |
| 07-31 | Barclays | Equal-weight | $80 |
| 07-31 | Baird | Neutral | $70 |
Quotes delayed. Options from Cboe delayed chain. Not investment advice, not a solicitation, and not affiliated with Moderna, Inc..